

Correction regarding notice of annual general meeting in Xbrane Biopharma

Xbrane Biopharma AB ("Xbrane") announces a correction of the notice of the annual general meeting published on 4 April 2022.

The correction, item 8-10, refers to the previous mandate of the proposed board member Kirsti Gjellan. Kirsti Gjellans has previously been a board member of PiiA, SwedenBio, OxThera and Pfizer Health AB. Xbrane Biopharma AB have today updated the notice and the full notice of the annual general meeting, to be held on 5 May 2022, is available on the company's website, www.xbrane.com.

Contacts

Martin Åmark, CEO
M: +46 76 309 37 77
E: martin.amark@xbrane.com

Anette Lindqvist, CFO/IR
M: +46 76 325 60 90
E: anette.lindqvist@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting SEK 332 billion in annual sales of the respective reference products, with the leading one under registration in Europe. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com

Attachments

[Correction regarding notice of annual general meeting in Xbrane Biopharma](#)